Evidence map›Paper›PMID 34951451›Full record

ArticleThe Journal of infectious diseases2022

Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old-New Vaccine Surveillance Network 2016-2017 and 2017-2018.

Sara S Kim, Eric A Naioti, Natasha B Halasa, Laura S Stewart, John V Williams, Marian G Michaels, Rangaraj Selvarangan, Christopher J Harrison, Mary A Staat, Elizabeth P Schlaudecker and 10 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sara S KimInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eric A NaiotiInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Natasha B HalasaVanderbilt University Medical Center, Nashville, Tennessee, USA.
Laura S StewartVanderbilt University Medical Center, Nashville, Tennessee, USA.
John V WilliamsDepartment of Pediatrics, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marian G MichaelsDepartment of Pediatrics, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Rangaraj SelvaranganDepartment of Pediatrics, Infectious Diseases Division, Children's Mercy-Kansas City and University of Missouri, Kansas City, Kansas City, Missouri, USA.ORCID 0000-0003-3275-6657
Christopher J HarrisonDepartment of Pediatrics, Infectious Diseases Division, Children's Mercy-Kansas City and University of Missouri, Kansas City, Kansas City, Missouri, USA.
Mary A StaatDepartment of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Elizabeth P SchlaudeckerDepartment of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Geoffrey A WeinbergUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Peter G SzilagyiUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Julie A BoomBaylor College of Medicine, Houston, Texas, USA.
Leila C SahniBaylor College of Medicine, Houston, Texas, USA.
Janet A EnglundSeattle Children's Hospital, Seattle, Washington, USA.
Eileen J KleinSeattle Children's Hospital, Seattle, Washington, USA.
Constance E OgokehInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Angela P CampbellInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Manish M PatelInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
New Vaccine Surveillance Network

Funding

IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus IllnessesU01IP001157 · IP · SEATTLE CHILDREN'S HOSPITAL · PI ENGLUND, JANET A, KLEIN, EILEEN · 2021 to 2025
$11.7M
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine EffectivenessU01IP001158 · IP · UNIVERSITY OF ROCHESTER · PI WEINBERG, GEOFFREY ALAN · 2021 to 2025
$10.2M
Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant RecipientsU01AI167799 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lara A DANZIGER-ISAKOV, NATASHA Bassam HALASA · 2023 to 2026
$6.7M
Enhanced Surveillance for Newly Preventable Diseases (ARI and AGE Surveillance) - Rochester, NYU01IP001049 · IP · UNIVERSITY OF ROCHESTER · PI WEINBERG, GEOFFREY ALAN · 2016 to 2020
$6.3M
Enhanced Surveillance for New Vaccine Preventable DiseasesU01IP001050 · IP · SEATTLE CHILDREN'S HOSPITAL · PI ENGLUND, JANET A, KLEIN, EILEEN · 2016 to 2020
$6.3M
Enhanced Surveillance for New Vaccine Preventable DiseasesU01IP001063 · IP · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HALASA, NATASHA BASSAM · 2016 to 2020
$6.3M
CDC HHS CDC-RFA-IP16-004NCIRD CDC HHS U01 IP000464NCIRD CDC HHS U01 IP001049NCIRD CDC HHS U01 IP001050NCIRD CDC HHS U01 IP001063NCIRD CDC HHS U01 IP001156NCIRD CDC HHS U01 IP001157NCIRD CDC HHS U01 IP001158NIAID NIH HHS U01 AI167799
6 · The paper itself

Abstract

Studies have shown egg-adaptive mutations in influenza vaccine strains that might have impaired protection against circulating A(H3N2) influenza viruses during the 2016-2017 and 2017-2018 seasons. We used the test-negative design and multivariable models to assess vaccine effectiveness against influenza-associated hospitalization and emergency department visits among children (<18 years old) during the 2016-2017 and 2017-2018 seasons. Effectiveness was 71% (95% confidence interval, 59%-79%), 46% (35%-55%), and 45% (33%-55%) against A(H1N1)pdm09, A(H3N2), and B viruses respectively, across both seasons. During high-severity seasons with concerns for vaccine mismatch, vaccination offered substantial protection against severe influenza outcomes requiring hospitalization or emergency department visits among children.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesAdolescentCase-Control StudiesChildEmergency Service, HospitalHospitalizationHumansInfluenza A Virus, H3N2 SubtypeInfluenza B virusSeasonsVaccinationVaccine EfficacyInfluenza VaccineschildrenInfluenzatest negative designvaccination

Identifiers

PMID34951451
PMCPMC13031992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.